Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

Weill Cornell Medicine researchers have discovered that PD-1—a molecule best known for putting the brakes on immune ...

Immutep is continuing the AIPAC-003 trial, which enrolled 71 metastatic hormone receptor positive (HR+), HER2-negative/low or ...

The global cancer biomarkers market is projected to rise from USD 28.6 billion in 2025 to USD 46.7 billion by 2035, at a 5% CAGR. Key growth areas in ...

AstraZeneca PLC ( NASDAQ: AZN) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

Weill Cornell Medicine researchers have discovered that PD-1—a molecule best known for putting the brakes on immune ...

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose ...

SUZHOU, China, July 29, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation ...